Tempus AI
Medical records run on two clocks, and only one of them is yours: retention law keeps the clinical file for years or decades whatever you ask. Around it, what you looked up can become an advertising interest, and a deletion request usually comes back half done.
Reported incidents
Sued for training AI on a genetic testing firm's data and supplying drug makers
2026-04-15Affected Ambry Genetics' genetic test database
Class actions against Tempus AI were consolidated on 15 April 2026 in federal court in the Northern District of Illinois as Farrier v. Tempus AI. Tempus bought the genetic testing company Ambry Genetics in February 2025 for $600 million. The plaintiffs say Tempus used Ambry's genetic records to train its AI models and gave genetic data to more than 70 drug and biotech companies, including AstraZeneca, Pfizer, Bristol Myers Squibb and GlaxoSmithKline, without written consent, in breach of Illinois' Genetic Information Privacy Act. They argue genetic data cannot be de-identified. The court has not ruled on the claims.
People affected typically ask Tempus AI to confirm whether their information was included, and which categories.
The verified route
DÆTRAX is a personal data accountability ledger: a dated record of which companies hold your personal data, what you asked them to do about it, and what they claimed in reply.